Drug intelligence / Profile preview

Petadol

Development stage: Unknown
Lead developer: Bioquest Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

Petadol is an ophthalmic solution developed and marketed by Bioquest Pharmaceuticals, primarily used for the treatment of allergic conjunctivitis. Its active ingredient is olopatadine, a small molecule that functions as a dual-action antihistamine and mast cell stabilizer. It works by selectively antagonizing the histamine H1 receptor and inhibiting the release of inflammatory mediators from mast cells in the conjunctiva. This mechanism effectively relieves symptoms such as ocular itching, redness, and watering associated with seasonal or perennial allergic reactions. Petadol is administered topically to the eye and is currently approved and available in the Indian market.

Brand names: Petadol
Other names: olopatadine

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Petadol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Petadol.

Explore the full profile